Dynamics and regulation of the oxidative stress response upon chemical exposure
Bischoff, L.J.M.

1

General introduction and aim of the thesis

There is an increasing number of chemicals that enters the society, including drugs, environmental chemicals and cosmetics, combined also referred as the chemical exposome. Likewise there is an increased hazard for chemically-induced health effects. Chemicals can interfere with biological systems and induce compound specific responses, either related to the pharmacological on- or off-target effects. In particular compounds with (in)direct electrophilic reactivity are of direct harm to cells. Such compounds will interfere with normal cellular physiological processes and activate adaptive cellular stress responses that try to repair the cellular injury. Understanding the fundamental relationship between activation of these cellular stress responses and ultimate onset of cytotoxicity can be used for constructing mechanism-based biomarkers.

CLASSIFICATION AND USE OF BIOMARKERS

To establish whether exposure to a certain chemical or drug did or did not occur, or what the unwanted consequences are from exposure to a chemical or drug, appropriate biomarkers are needed. The broad definition of a biomarker, as stated by the World Health Organization (WHO), is: a biomarker is almost any measurement reflecting an interaction between a biological system and an environmental agent, which may be chemical, physical or biological (WHO, 1993). A more specific definition of a biomarker given by the WHO is: a biomarker is any substance, structure or process that can be measured in the body or its products and influence or predict the incidence or outcome of disease (WHO, 2001). The role of a biomarker can be interpreted as a "fingerprint" left behind in the body after exposure (with the analogy of the body as a "crime scene"). Many different classification systems of biomarkers are described in literature based on the information they provide or their intended use. Although classification of biomarkers in certain categories might be useful, one has to keep in mind that biomarkers might fit in different categories, depending on the knowledge we have regarding their link to the chemical exposure or disease mechanisms, as well as their intended use in a particular situation.

Manno et al. (2010), describes a classification system where biomarkers are divided in three different groups depending on their toxicological significance: biomarkers of susceptibility, biomarkers of exposure and biomarkers of effect (Manno et al. 2010). Another method of classification is described by Baker et al. (2005), who classifies biomarkers concerning their applications, for example: disease biomarkers and toxicity biomarkers (Baker 2005). Furthermore, with advancement in technology and knowledge of biological pathways and disease mechanisms, came the use of

biomarker panels, constructed of multiple biomarkers e.g. multiple genes or proteins representing a specific stress pathway, like for example inflammation. Based on this, Robinson et al. (2013), introduced the concept of "actionable" biomarkers, biomarkers that can be used to guide clinical management of disease and could even be used to diagnose diseases in their early, asymptomatic state (Robinson et al. 2013) (Figure 1). Two types of "actionable" biomarkers described by Robinson et al. (2013), are mechanistic biomarkers, which play a role in the mechanism of the disease, and descriptive biomarkers, which are not directly involved in the mechanism of disease, but are rather products of the disease or the damage induced by the disease. Antoine et al. (2013), describe a mechanistic biomarker for early and sensitive detection of acetaminophen-induced acute liver injury. They described a plasma derived biomarker panel consisting of miR-122, a microRNA highly specific for the liver, high mobility group box 1 (HMGB1) a marker of necrosis, and caspase-cleaved keratin-18 (K18) a marker of necrosis and apoptosis (Antoine et al. 2013). This biomarker panel proved to be more sensitive than the measurement of alanine transaminase (ALT) a well-established biomarker for assessing the health status of the liver. This indicates that mechanistic biomarkers existing of several proteins and microRNAs related to certain stress response pathways, can provide information concerning the molecular mechanisms of action of a chemical upon exposure. In the field of pharmacology, there is great need for mechanistic biomarkers, as these markers might have the ability to predict the response of a drug and thereby provide information which can be used to develop personal-based medicine approaches (Amadoz et al. 2015). However, it might be clear that for the construction of these (mechanistic) biomarker panels a greater understanding is needed regarding the different players (proteins, genes, microRNAs) of the different stress response pathways, as well as their interactions and changes over time (dynamics of the stress response pathway). Therefore, guided by the advancement in omics techniques, much research is targeted on unraveling the mechanisms of stress response pathways such as the DNA-damage response, unfolded protein response, and oxidative stress response. Moreover, microRNAs are promising small non-coding RNAs that could serve as biomarkers for small injury and can also modulate cellular biology including toxic responses. Since oxidative stress and microRNAs are central in this thesis, below these topics will be specifically addressed in some detail.

1. Diagnosis of asymptomatic disease in at-risk populations (diagnostic)
2. Early diagnosis of symptomatic disease (diagnostic)
3. Disease prognosis (prognostic)
4. Improved diagnosis of symptomatic disease (diagnostic)
5. Selection of appropriate therapy (predictive)
6. Assessment of response to therapy or disease progression (Pharmacodynamics)

Time

5-6

4-6

2-3

1

Figure 1. Use of actionable biomarkers over time.
(Modified from Robinson et al. 2013).

THE OXIDATIVE STRESS RESPONSE PATHWAY

In a cell there is a continuous production of reactive oxygen (ROS) and nitrogen species (RNS) (Finkel and Holbrook 2000). ROS and RNS are generated as a result of internal metabolism, for example aerobic respiration in mitochondria, and exposure to exogenous toxicants (Filomeni et al. 2015; Ma 2013; Turrens 2003). A controlled production of ROS and RNS has been described in literature to contribute to the regulation of various physiological processes in the cell like proliferation, autophagy and inflammation (Finkel 2011). However, uncontrolled production of ROS and RNS, called oxidative stress, can result in inflammatory responses and eventually lead to pathological conditions like cancer and neurodegenerative disorders (Prasad et al. 2017).

To overcome oxidative stress, a cell has several mechanisms to protect itself against oxidative stress. One of the most important mechanisms against oxidative stress is the Nrf2 pathway (Figure 2), named after its transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2). Not surprisingly, the Nrf2 pathway plays a role

in many diseases including cancer and neurodegenerative diseases like Alzheimer's disease (Bryan et al. 2013; Deshmukh et al. 2017). It is reported that in many different tumor cells Nrf2 is overexpressed, consequently making these cells less vulnerable for chemotherapy (Kensler and Wakabayashi 2010; Ren et al. 2011; Tang et al. 2011; Wang et al. 2008).


Figure 2. The Nrf2 pathway: the "cyclic sequential attachment and regeneration" model.

Nuclear factor E2-related factor 2 (Nrf2) is a transcription factor that upregulates expression of a battery of genes to combat oxidative and electrophilic stress. Modification of Kelch-like ECH-associated protein 1 (Keap1) by reactive oxygen species stabilizes Nrf2 by escaping from degradation. Nrf2 then is able to move freely to the nucleus, were it activates many different antioxidants like Srxn1.

Canonical activation of the Nrf2 pathway

In basal conditions, Nrf2 is bound in the cytoplasm to two Kelch-like ECH-associated protein 1 proteins (Keap1) (Keum and Choi 2014; Zipper and Mulcahy 2002). Nrf2 consist of seven functional domains (Neh1 – Neh7). Of these domains Neh2 contains seven lysine residues, which plays a role in the ubiquitination of Nrf2 (Itoh et al. 1999; Zhang et al. 2004), which facilitates the destruction of Nrf2 via the ubiquitin-26S proteasomal pathway (Kobayashi et al. 2004). Furthermore, the Neh2 domain contains two binding sites which interact with Keap1. These are the ETGE and DLG motives (McMahon et al. 2006).

Keap1 is an adaptor for Cullin-3 (Cul3)-based E3 ubiquitin ligase, which facilitates poly-ubiquitin conjugation to Nrf2, and therefore degradation by the proteasome

(Kobayashi et al. 2004). Keap1 consists of three functional domains. A broad complex/tramtrack/bric-a-brac (BTB) domain, which binds to Cul3 and is required for the dimerization of Keap1 (Zipper and Mulcahy 2002). An intervening region (IVR), and a kelch/double glycine repeat (DGR) domain, which interacts with the Neh2 domain of Nrf2 (Canning et al. 2015). Furthermore, human Keap1 contains 27 cysteine residues (Zhang and Hannink 2003). These cysteine residues can interact with ROS and electrophilic compounds, leading to Nrf2 pathway activation. Interestingly, chemicals show different affinity for the different cysteine groups (Takaya et al. 2012).

In literature, different models can be found describing how, upon activation, Nrf2 enters the nucleus to bind to the antioxidant response element (ARE) and starts the transcription of different antioxidants. Early models described total dissociation of Nrf2 from Keap1, but latest understanding suggest models like the 'two-site recognition hinge-and-latch' and abended the idea of total dissociation of Nrf2 from Keap1. The two-site recognition hinge-and-latch model, is named after the Nrf2 motives ETGE (hinge) and DLG (latch) (Tong et al. 2006b). Keap1 has a higher affinity for the hinge than for the latch (Tong et al. 2006a). Subsequently, Keap1 binds first to the ETGE domain and after the connection is established to the DLG domain.

Covalent binding of ROS or reactive metabolites to one of the cysteine groups of Keap1 is thought to induce a conformational change in the IVR domain of Keap1, decreasing the binding from Keap1 with Cul3 and dissociation of the DLG domain (Cleasby et al. 2014). The ETGE domain, which has a tighter interaction than the DLG domain, does not dissociate from Keap1 (Suzuki and Yamamoto 2015; Tong et al. 2007). Moreover, because of the dissociation of the DLG domain, Nrf2 is not targeted for degradation. As a consequence, *de novo* synthesized Nrf2 is able to translocate to the nucleus. In the nucleus Nrf2 will bind to the ARE, together with members of the masculoaponeurotic fibrosarcoma (Maf) proteins (MafF, MafG and MafK), which facilitates binding to the ARE. Binding to the ARE results in the transcription of different cytoprotective genes involved in e.g. glutathione metabolism, phase 2 drug-metabolizing enzymes and antioxidant response proteins as, for example, sulfiredoxin1 (Srxn1), hemeoxygenase 1 (Hmox1), and NAD(P)H-quinone oxidoreductase 1 (Nqo1) (Hayes et al. 2010; Zhang and Gordon 2004).

In parallel with the above described inhibition of ubiquitination of Nrf2, binding of an electrophilic compound can trigger the ubiquitination of Keap1 by the Cul3-Rbx1 complex decreasing the levels of Keap1, resulting in the movement of *de novo* synthesized Nrf2 into the nucleus (Hong et al. 2005). Unlike degradation of ubiquitinated Nrf2, Keap1 degradation is independent of the proteasome pathway (Zhang et al. 2005).

Different mechanisms of Nrf2 pathway termination are described in literature. Sun et al. (2007), suggest a mechanism whereby Nrf2 is transported back to the cytoplasm by Keap1, which has a nuclear export sequence (Sun et al. 2007). Furthermore, transcription regulator protein Bach1 can bind to the ARE and is therefore able to compete with Nrf2 (Tkachev et al. 2011). Kaspar and Jaiswal (2010), describes that Nrf2 regulates its own degradation through increasing Cul3-Rbx1 expression upon binding to the ARE and thereby inducing promoter activity of Cul3-Rbx1 genes (Kaspar and Jaiswal 2010).

Interactions with other adaptive pathways: non-canonical Nrf2 pathway activation

Numerous studies describe the interaction of the Nrf2 pathway with other adaptive stress response pathways like, for example, the DNA-damage response, the unfolded protein response and the NF-κB-signaling pathway.

Interaction with the DNA damage response
Faraonio et al. (2006), showed that p53, a key player in the DNA damage response, negatively regulates Nrf2-mediated gene transcription (Faraonio et al. 2006). However, the KRR motif in p21, a downstream target of p53, is able to bind to the DLG and ETGE motifs within Nrf2, blocking the binding of Nrf2 with Keap1. Consequently, ubiquitination cannot take place, which in turn leads to activation of the Nrf2 pathway (Chen et al. 2009).

Interaction with the unfolded protein response
Oxidative stress can result in endoplasmic reticulum stress (ERS) (Digaleh et al. 2013). ERS might in turn lead to activation of the unfolded protein response (UPR). The UPR roughly exists of three major branches, which consists of three transmembrane sensors: transcription factor 6 (ATF6), inositol-requiring enzyme-1α (IRE1) and protein kinase-like ER kinase (PERK) (Hetz 2012). PERK-dependent phosphorylation promotes the dissociation of Nrf2 from keap1, and therefore activation of the Nrf2 pathway (Cullinan et al. 2003; Zhu et al. 2015).

Interaction with the NF-κB-signaling pathway
Wardyn et al. (2015), described the crosstalk between NF-κB and Nrf2, with increased activity of NF-κB in the absence of Nrf2 (Wardyn et al. 2015). Furthermore, ROS can oxidize cysteine residues in the DNA binding domain of NF-κB (Hirota et al. 1999). Moreover, IκB kinase β (IKKβ) is a substrate analogue of Keap1 (Kim et al. 2010). Jiang et al. (2013), found that, like Nrf2, IKKβ has a ETGE motif (Jiang et al. 2013). This makes it possible for IKKβ to bind to Keap1, and therefore to compete with Nrf2. Consequently, Keap1 is responsible for IKKβ ubiquitination and therefore

degradation, and therefore downregulation of NF-κB (Lee et al. 2009). Furthermore, AP-1 factors as c-Fos and Jun-D are also known to bind to the ARE. Binding of these factors blocks the binding side of the ARE for Nrf2 resulting in a decrease of its downstream targets (Li and Jaiswal 1992; Venugopal and Jaiswal 1996; Wilkinson et al. 1998). Recently it became clear that besides genes and proteins another class of signaling molecules play an important role in the regulation of stress response pathways: microRNAs.

MICRORNAS

MicroRNAs (miRNAs or miRs) are small (~22-nt) non-coding RNAs (Starega-Roslan et al. 2010). MicroRNAs regulate gene expression at the post-transcriptional level and are involved in many biological processes. MicroRNA target sites are typically located on the 3'untranslated region of their target mRNAs. These target sites only needs to be partially complementary to the microRNA (Lam et al. 2015), which leads to target mRNA translational repression or degradation (Djuranovic et al. 2012; Filipowicz et al. 2008). A single microRNA can have about 100 target sites (Brennecke et al. 2005), and mRNAs can be targeted by more than one single microRNA (Peter 2010; Wu et al. 2010).

MicroRNAs are involved in many physiological processes including the immune response, metabolism, and development (Hou et al. 2011). Furthermore, microRNAs are involved in toxicological responses (Mendell and Olson 2012) including activation/inhibition of stress response pathways (Bartoszewska et al. 2013). Therefore microRNAs also play a role in diseases like, for example, (various types of) cancer (Meng et al. 2016) and other pathologies like acute myocardial infarction (Devaux et al. 2012). Moreover, some microRNAs exists which are highly "tissue specific", meaning they are abundantly present in a certain tissue type, as for example miR-122 is tissue specific for the liver. Measurement of these microRNAs might provide information regarding the organs which are damaged upon chemical exposure, because of their high concentration in the bloodstream after tissue damage occurred (Laterza et al. 2009). Altogether, these features make microRNAs interesting candidates for biomarkers for exposure and disease.

Understanding the fundamental relationship between activation of cellular stress responses and ultimate onset of cytotoxicity is of critical importance. As described above, knowledge of stress pathway behavior on protein, gene, and microRNA level can be applied in the construction of a mechanistic biomarker fingerprint.

THESIS OUTLINE

The focus of the described research in this thesis is on the oxidative stress response (Nrf2 pathway). The aim of the research presented in this thesis is to obtain more information concerning microRNAs which are involved in the Nrf2 pathway to determine and evaluate the application of microRNAs for the construction of novel mechanistic biomarkers. Furthermore, we aimed to obtain a better understanding with respect to the dynamics of the Nrf2 pathway to repeated xenobiotic exposure. In **Chapter 2**, microRNAs are introduced and their utility as biomarkers of chemical exposure and disease (effect) is reviewed in respect to the current knowledge of this upcoming field. As shown in **Chapter 2**, exposure to chemicals can lead to overexpression of certain microRNAs. In **Chapter 3**, to investigate the effect of overexpression of microRNAs on the Nrf2 pathway response in general and in combination with chemical exposure, a microRNA mimic screen was performed. In this screen overexpression of microRNAs was induced by using synthetic microRNA mimics. Since repeated exposure may drive adaptation programs and may lead to different responses between single and repeated exposures, in **Chapter 4** the effect of a second exposure on the dynamics of the Nrf2 pathway activation was conducted. In **Chapter 5** results of a study are shown where a panel of structurally different phenolic compounds were used to demonstrate the proof-of-concept that Nrf2 pathway reporters can successfully be applied as biomarkers to characterize the specific pro-oxidant responses of chemicals. Finally, in **Chapter 6** the findings of the studies described in this thesis are discussed and an overview is provided concerning future perspectives and implications of the included studies.

REFERENCES

Amadoz A, Sebastian-Leon P, Vidal E, Salavert F, Dopazo J (2015) Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity. Sci Rep 5:18494 doi:10.1038/srep18494

Antoine DJ, Dear JW, Lewis PS, et al. (2013) Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 58(2):777-87 doi:10.1002/hep.26294

Baker M (2005) In biomarkers we trust? Nature Biotechnology 23(3):297-304 doi:10.1038/nbt0305-297

Bartoszewska S, Kochan K, Madanecki P, et al. (2013) Regulation of the unfolded protein response by microRNAs. Cell Mol Biol Lett 18(4):555-578 doi:10.2478/s11658-013-0106-z

Brennecke J, Stark A, Russell RB, Cohen SM (2005) Principles of microRNA-target recognition. PLoS Biol 3(3):e85 doi:10.1371/journal.pbio.0030085

Bryan HK, Olayanju A, Goldring CE, Park BK (2013) The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol 85(6):705-17 doi:10.1016/j.bcp.2012.11.016

Canning P, Sorrell FJ, Bullock AN (2015) Structural basis of Keap1 interactions with Nrf2. Free Radic Biol Med 88(Pt B):101-107 doi:10.1016/j.freeradbiomed.2015.05.034

Chen W, Sun Z, Wang XJ, et al. (2009) Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 34(6):663-73 doi:10.1016/j.molcel.2009.04.029

Cleasby A, Yon J, Day PJ, et al. (2014) Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO. PLoS One 9(6):e98896 doi:10.1371/journal.pone.0098896

Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, Diehl JA (2003) Nrf2 Is a Direct PERK Substrate and Effector of PERK-Dependent Cell Survival. Molecular and Cellular Biology 23(20):7198-7209 doi:10.1128/mcb.23.20.7198-7209.2003

Deshmukh P, Unni S, Krishnappa G, Padmanabhan B (2017) The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev 9(1):41-56 doi:10.1007/s12551-016-0244-4

Devaux Y, Vausort M, Goretti E, et al. (2012) Use of Circulating MicroRNAs to Diagnose Acute Myocardial Infarction. Clinical Chemistry 58(3):559 doi:10.1373/clinchem.2011.173823

Digaleh H, Kiaei M, Khodagholi F (2013) Nrf2 and Nrf1 signaling and ER stress crosstalk: implication for proteasomal degradation and autophagy. Cellular and Molecular Life Sciences 70(24):4681-4694 doi:10.1007/s00018-013-1409-y

Djuranovic S, Nahvi A, Green R (2012) miRNA-Mediated Gene Silencing by Translational Repression Followed by mRNA Deadenylation and Decay. Science 336(6078):237 doi:10.1126/science.1215691

Faraonio R, Vergara P, Di Marzo D, et al. (2006) p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem 281(52):39776-84 doi:10.1074/jbc.M605707200

Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature Reviews Genetics 9(2):102-114 doi:10.1038/nrg2290

Filomeni G, De Zio D, Cecconi F (2015) Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death Differ 22(3):377-388 doi:10.1038/cdd.2014.150

Finkel T (2011) Signal transduction by reactive oxygen species. The Journal of Cell Biology 194(1):7 doi:10.1083/jcb.201102095

Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408(6809):239-247 doi:10.1038/35041687

Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT (2010) Cancer Chemoprevention Mechanisms Mediated Through the Keap1–Nrf2 Pathway. Antioxidants & Redox Signaling 13(11):1713-1748 doi:10.1089/ars.2010.3221

Hetz C (2012) The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nature Reviews Molecular Cell Biology 13(2):89-102 doi:10.1038/nrm3270

Hirota K, Murata M, Sachi Y, et al. (1999) Distinct Roles of Thioredoxin in the Cytoplasm and in the Nucleus: A TWO-STEP MECHANISM OF REDOX REGULATION OF TRANSCRIPTION FACTOR NF-κB. Journal of Biological Chemistry 274(39):27891-27897 doi:10.1074/jbc.274.39.27891

Hong F, Sekhar KR, Freeman ML, Liebler DC (2005) Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. J Biol Chem 280(36):31768-75 doi:10.1074/jbc.M503346200

Hou L, Wang D, Baccarelli A (2011) Environmental chemicals and microRNAs. Mutat Res 714(1-2):105-12 doi:10.1016/j.mrfmmm.2011.05.004

Itoh K, Wakabayashi N, Katoh Y, et al. (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes & Development 13(1):76-86 doi:10.1101/gad.13.1.76

Jiang Z-Y, Chu H-X, Xi M-Y, et al. (2013) Insight into the Intermolecular Recognition Mechanism between Keap1 and IKKβ Combining Homology Modelling, Protein-Protein Docking, Molecular Dynamics Simulations and Virtual Alanine Mutation. PLOS ONE 8(9):e75076 doi:10.1371/journal.pone.0075076

Kaspar JW, Jaiswal AK (2010) An autoregulatory loop between Nrf2 and Cul3-Rbx1 controls their cellular abundance. J Biol Chem 285(28):21349-58 doi:10.1074/jbc.M110.121863

Kensler TW, Wakabayashi N (2010) Nrf2: friend or foe for chemoprevention? Carcinogenesis 31(1):90-9 doi:10.1093/carcin/bgp231

Keum YS, Choi BY (2014) Molecular and chemical regulation of the Keap1-Nrf2 signaling pathway. Molecules 19(7):10074-89 doi:10.3390/molecules190710074

Kim J-E, You D-J, Lee C, Ahn C, Seong JY, Hwang J-I (2010) Suppression of NF-κB signaling by KEAP1 regulation of IKKβ activity through autophagic degradation and inhibition of phosphorylation. Cellular Signalling 22(11):1645-1654 doi:https://doi.org/10.1016/j.cellsig.2010.06.004

Kobayashi A, Kang MI, Okawa H, et al. (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24(16):7130-9 doi:10.1128/MCB.24.16.7130-7139.2004

Lam JKW, Chow MYT, Zhang Y, Leung SWS (2015) siRNA Versus miRNA as Therapeutics for Gene Silencing. Molecular Therapy - Nucleic Acids 4:e252 doi:https://doi.org/10.1038/mtna.2015.23

Laterza OF, Lim L, Garrett-Engele PW, et al. (2009) Plasma MicroRNAs as Sensitive and Specific Biomarkers of Tissue Injury. Clinical Chemistry 55(11):1977 doi:10.1373/clinchem.2009.131797

Lee D-F, Kuo H-P, Liu M, et al. (2009) KEAP1 E3 Ligase-Mediated Downregulation of NF-κB Signaling by Targeting IKKβ. Molecular Cell 36(1):131-140 doi:https://doi.org/10.1016/j.molcel.2009.07.025

Li Y, Jaiswal AK (1992) Regulation of human NAD(P)H:quinone oxidoreductase gene. Role of AP1 binding site contained within human antioxidant response element. Journal of Biological Chemistry 267(21):15097-104

Ma Q (2013) Role of Nrf2 in Oxidative Stress and Toxicity. Annual Review of Pharmacology and Toxicology 53(1):401-426 doi:10.1146/annurev-pharmtox-011112-140320

Manno M, Viau C, in collaboration w, et al. (2010) Biomonitoring for occupational health risk assessment (BOHRA). Toxicol Lett 192(1):3-16 doi:10.1016/j.toxlet.2009.05.001

McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD (2006) Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J Biol Chem 281(34):24756-68 doi:10.1074/jbc.M601119200

Mendell JT, Olson EN (2012) MicroRNAs in stress signaling and human disease. Cell 148(6):1172-87 doi:10.1016/j.cell.2012.02.005

Meng X, Müller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H (2016) Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget 7(13):16923-16935 doi:10.18632/oncotarget.7850

Peter ME (2010) Targeting of mRNAs by multiple miRNAs: the next step. Oncogene 29(15):2161-2164 doi:10.1038/onc.2010.59

Prasad S, Gupta SC, Tyagi AK (2017) Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals. Cancer Lett 387:95-105 doi:10.1016/j.canlet.2016.03.042

Ren D, Villeneuve NF, Jiang T, et al. (2011) Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A 108(4):1433-8 doi:10.1073/pnas.1014275108

Robinson WH, Lindstrom TM, Cheung RK, Sokolove J (2013) Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nat Rev Rheumatol 9(5):267-76 doi:10.1038/nrrheum.2013.14

Starega-Roslan J, Krol J, Koscianska E, et al. (2010) Structural basis of microRNA length variety. Nucleic Acids Research 39(1):257-268 doi:10.1093/nar/gkq727

Sun Z, Zhang S, Chan JY, Zhang DD (2007) Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2. Mol Cell Biol 27(18):6334-49 doi:10.1128/MCB.00630-07

Suzuki T, Yamamoto M (2015) Molecular basis of the Keap1-Nrf2 system. Free Radic Biol Med 88(Pt B):93-100 doi:10.1016/j.freeradbiomed.2015.06.006

Takaya K, Suzuki T, Motohashi H, et al. (2012) Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. Free Radic Biol Med 53(4):817-27 doi:10.1016/j.freeradbiomed.2012.06.023

Tang X, Wang H, Fan L, et al. (2011) Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med 50(11):1599-609 doi:10.1016/j.freeradbiomed.2011.03.008

Tkachev VO, Menshchikova EB, Zenkov NK (2011) Mechanism of the Nrf2/Keap1/ARE signaling system. Biochemistry (Moscow) 76(4):407-422 doi:10.1134/s0006297911040031

Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M (2006a) Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol Cell Biol 26(8):2887-900 doi:10.1128/MCB.26.8.2887-2900.2006

Tong KI, Kobayashi A, Katsuoka F, Yamamoto M (2006b) Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. Biol Chem 387(10-11):1311-20 doi:10.1515/BC.2006.164

Tong KI, Padmanabhan B, Kobayashi A, et al. (2007) Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol Cell Biol 27(21):7511-21 doi:10.1128/MCB.00753-07

Turrens JF (2003) Mitochondrial formation of reactive oxygen species. J Physiol 552(Pt 2):335-44 doi:10.1113/jphysiol.2003.049478

1

Venugopal R, Jaiswal AK (1996) Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase<sub>1</sub>gene. Proceedings of the National Academy of Sciences 93(25):14960 doi:10.1073/pnas.93.25.14960

Wang XJ, Sun Z, Villeneuve NF, et al. (2008) Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29(6):1235-43 doi:10.1093/carcin/bgn095

Wardyn JD, Ponsford AH, Sanderson CM (2015) Dissecting molecular cross-talk between Nrf2 and NF-κB response pathways. Biochem Soc Trans 43(4):621-626 doi:10.1042/BST20150014

Wilkinson J, Radjendirane V, Pfeiffer GR, Jaiswal AK, Clapper ML (1998) Disruption of c-Fos Leads to Increased Expression of NAD(P)H:Quinone Oxidoreductase1 and GlutathioneS-Transferase. Biochemical and Biophysical Research Communications 253(3):855-858 doi:https://doi.org/10.1006/bbrc.1998.9804

Wu S, Huang S, Ding J, et al. (2010) Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region. Oncogene 29(15):2302-2308 doi:10.1038/onc.2010.34

Zhang DD, Hannink M (2003) Distinct Cysteine Residues in Keap1 Are Required for Keap1-Dependent Ubiquitination of Nrf2 and for Stabilization of Nrf2 by Chemopreventive Agents and Oxidative Stress. Molecular and Cellular Biology 23(22):8137-8151 doi:10.1128/mcb.23.22.8137-8151.2003

Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M (2004) Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24(24):10941-53 doi:10.1128/MCB.24.24.10941-10953.2004

Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, Hannink M (2005) Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. J Biol Chem 280(34):30091-9 doi:10.1074/jbc.M501279200

Zhang Y, Gordon GB (2004) A strategy for cancer prevention: Stimulation of the Nrf2-ARE signaling pathway. Molecular Cancer Therapeutics 3(7):885

Zhu YF, Li XH, Yuan ZP, et al. (2015) Allicin improves endoplasmic reticulum stress-related cognitive deficits via PERK/Nrf2 antioxidative signaling pathway. Eur J Pharmacol 762:239-46 doi:10.1016/j.ejphar.2015.06.002

Zipper LM, Mulcahy RT (2002) The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J Biol Chem 277(39):36544-52 doi:10.1074/jbc.M206530200